NCT00739596CompletedPhase 4
An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 332
- Locations
- 1
- Primary Endpoint
- Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment
Study Overview
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.
- •Men or women 18 years and older of African American background; self identified
- •Patients with stage 2 hypertension. Patients must have a MSSBP ≥ 160 mmHg and < 200 mmHg at Visit 5 (randomization)
Exclusion Criteria
- •Office blood pressure measured by cuff (MSSBP ≥ 200 mmHg and/or MSDBP ≥ 110 mmHg) at any visit.
- •Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives whichever is longer.
- •History of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class (CCBs or thiazide diuretics) as the study drugs.
- •Long QT syndrome or QTc > 450 msec for males and > 470 msec for females at screening.
- •History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method.
- •Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.
- •Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [and estradiol < 20 pg/mL] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- •History or evidence of a secondary form of hypertension.
- •Known Keith-Wagener Grade III or IV hypertensive retinopathy.
- •History of cerebrovascular accident, transient ischemic cerebral attack (TIA), heart failure (NYHA Class II-IV), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI) in the last 12 months.
- •Current angina pectoris requiring pharmacological therapy.
- •Other protocol-defined inclusion/exclusion criteria may apply
Outcomes
Primary Outcomes
Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment
Time Frame: Baseline and 8 weeks
To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.
Secondary Outcomes
- Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment(Baseline and 8 weeks)
- Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment(Baseline and 8 weeks)
- Percentage of Responders After 8 Weeks of Treatment.(8 weeks)
- Percentage of Participants Achieving BP Control After 8 Weeks of Treatment(8 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With HypertensionHypertensionNCT00387517Novartis726
Completed
Phase 4
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older PopulationHypertensionNCT00760266Novartis451
Completed
Phase 3
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of AmlodipineHypertensionNCT00294710Novartis976
Completed
Phase 3
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of AmlodipineHypertensionNCT00219154Novartis1,125
Completed
Phase 3
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)Myocardial InfarctionNCT00414609Novartis820